Objective:

The PPD™ CorEvitas™ Myasthenia Gravis (MG) Registry was launched in October 2025 to evaluate long-term real-world safety and effectiveness of treatments for MG. 

Background:

Autoimmune MG, a rare disorder of the neuromuscular junction, manifests with fluctuating muscle weakness and fatigue, impairing daily function and quality of life (1, 2). In 2021, the estimated incidence and prevalence of MG in the US were 3.1 and 37 per 100,000 persons, respectively, and are increasing (4). Recently approved medications for MG have demonstrated significant improvements in patient function and disease activity in the context of randomized clinical trials. Real-world evidence is critical to understanding longer-term safety and effectiveness of treatments. 

Design/Methods:

The CorEvitas MG Registry is a prospective, observational cohort for adult patients with ocular and generalized forms of MG under the care of a neurologist in the US. Longitudinal data are collected from both patients and their treating physicians during routine clinical encounters under a structured and standardized data collection protocol. Patients may enroll if they start an enrollment-eligible medication non-steroidal immunosuppressants, complement inhibitors, neonatal Fc receptor (FcRn) inhibitors, or B-cell depleting agents at or within 12 months from enrollment. 

Results:

Initial size of the registry site network will comprise  ~50 US neurological practices, though there is no defined upper or lower limit on the number of patients or sites expected to participate. Data collected from patients and providers will include sociodemographic and lifestyle factors, prevalent and incident comorbidities/adverse events, disease activity measures (i.e. MG Composite [MGC], MG Impairment Index [MGII]) and validated patient-reported outcomes (MGQoL-15r, MG-ADL), exacerbations and crisis, and medication utilization. 

Conclusions:

The CorEvitas MG Registry will provide a rich source of data for examining the real-world comparative effectiveness and safety of recently approved and standard of care therapies as the treatment landscape for MG continues to evolve.